SARS–CoV-2–specific T cell responses and correlations with COVID-19 patient predisposition
Open accessThe DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). So far, viral targets of cellular immunity and factors determining successful mounting of T cell responses are poorly defined. We therefore analyzed cellular responses to membrane, nucleocapsid, and spike proteins in individuals suffering from moderate or severe infection and in individuals who recovered from mild disease. We demonstrate that the CoV-2-specific CD4+ T helper cell response is directed against all 3 proteins with comparable magnitude, ex vivo proliferation, and portions of responding patients. However, individuals who died were more likely to have not mounted a cellular response to the proteins. Higher patient age and comorbidity index correlated with increased frequencies of CoV-2-specific CD4+ T cells, harboring higher portions of IL-2-secreting, but lower portions of IFN-γ-secreting, cells. Diminished frequencies of membrane protein-reactive IFN-γ+ T cells were particularly associated with higher acute physiology and chronic health evaluation II scores in patients admitted to intensive care. CoV-2-specific T cells exhibited elevated PD-1 expression in patients with active disease as compared with those individuals who recovered from previous mild disease. In summary, our data suggest a link between individual patient predisposition with respect to age and comorbidity and impairment of CoV-2-specific Th1-type cellular immunity, thereby supporting a concept of altered T cell function in at-risk patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“suggesting a link between individual patient predisposition with respect to age and comorbidity [127, 128].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263 · cited 1×
“Interestingly, both risk factors overlap with those identified to generally predict mortality in a recent retrospective study (22).”
BackgroundAPACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
Le Gall, J.-R. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.270.24.2957 · Cited by 7,773
APACHE II: a severity of disease classification system.
Knaus, W. A., Draper, E. S., Wagner, D. P., & Zimmerman, J. E. (1985) · PubMed · Cited by 6,034
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750 · cited 1×
“Consequently, 2 recent reports verified that patients with COVID-19 exhibit a trend toward lower frequencies IFN-γ+ cells after unspecific stimulation (20, 21), an observation that could be confirmed by using the polyclonal stimulus SEB.”
ResultA Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia
Fine, M. J., Auble, T. E., Yealy, D. M., Hanusa, B. H., Weissfeld, L. A., Singer, D. E., Coley, C. M., Marrie, T. J., & Kapoor, W. N. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701233360402 · Cited by 4,582
Cited by
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102214 · Cited by 1,257
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · doi:10.1101/2021.02.10.21251247 · Cited by 1,257
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
Ferretti, A. P., Kula, T., Wang, Y., Nguyen, D. M. V., Weinheimer, A., Dunlap, G. S., Xu, Q., Nabilsi, N., Perullo, C. R., Cristofaro, A. W., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.006 · Cited by 318
Immunological memory to SARS‐CoV‐2 infection and COVID‐19 vaccines
Sette, A., & Crotty, S. (2022) · Immunological Reviews · doi:10.1111/imr.13089 · Cited by 269
“Pre-existing comorbidities in COVID patients have been reported to affect magnitude and helper T cell subset composition 128 .”
Gallo, O., Locatello, L. G., Mazzoni, A., Novelli, L., & Annunziato, F. (2021) · Mucosal Immunology · doi:10.1038/s41385-020-00359-2 · Cited by 248
“specific CD4+ T cells is higher in patients with severe COVID-19 compared to those with moderate disease, although with reduced proportions of IFN-γ secreting cells.(120) Increased frequencies of SARS-CoV-2 specific CD8+ T cells were observed in mild cases, suggesting that impaired cytotoxic T cell response may predis…”
BackgroundSattler, A., Schrezenmeier, E., Weber, U. A., Potekhin, A., Bachmann, F., Straub-Hohenbleicher, H., Budde, K., Storz, E., Proß, V., Bergmann, Y., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci150175 · Cited by 246
Self-citationDiscordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection
Reynolds, C. J., Swadling, L., Gibbons, J. M., Pade, C., Jensen, M. P., Diniz, M. O., Schmidt, N. M., Butler, D. K., Amin, O. E., Bailey, S. N. L., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abf3698 · Cited by 200
Riou, C., du Bruyn, E., Stek, C., Daroowala, R., Goliath, R. T., Abrahams, F., Said-Hartley, Q., Allwood, B. W., Hsiao, N.-Y., Wilkinson, K. A., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149125 · Cited by 183
“Both analyses showed that based on the functional and phenotypic traits of SARS-CoV-2 responding CD4 T cells, COVID-19 patients could be discriminated from non-COVID-19 controls.”
Triggle, C. R., Bansal, D., Ding, H., Islam, M. M., Farag, E. A. B. A., Hadi, H. A., & Sultan, A. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.631139 · Cited by 177
“The CD4+ T-cell response predominantly consisted of T-helper-1 (Th1) cells, characterized by high concentrations of IFN-γ secretion directed against both structural (spike, nucleocapsid and membrane) proteins and non-structural proteins (146, 147).”
BackgroundT cell apoptosis characterizes severe Covid-19 disease
André, S., Picard, M., Cezar, R., Roux-Dalvai, F., Alleaume-Butaux, A., Soundaramourty, C., Cruz, A. S., Mendes-Frias, A., Gotti, C., Leclercq, M., et al. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00936-x · Cited by 176
“Several reports also indicated a lack of anti–spike IgG response in cellular non-responders to SARS-CoV-2 antigens [61] that is more pronounced in males than in females [2].”
BackgroundBayart, J., Douxfils, J., Gillot, C., David, C., Mullier, F., Elsen, M., Eucher, C., Eeckhoudt, S. V., Roy, T., Gérin, V., et al. (2021) · Vaccines · doi:10.3390/vaccines9101092 · Cited by 138
Friedman, M., Curtis, J. R., & Winthrop, K. L. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221244 · Cited by 137
Keeton, R., Richardson, S. I., Moyo-Gwete, T., Hermanus, T., Tincho, M. B., Benede, N., Manamela, N. P., Baguma, R., Makhado, Z., Ngomti, A., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.10.003 · Cited by 111
Contribution of STAT3 to the pathogenesis of COVID-19
Jafarzadeh, A., Nemati, M., & Jafarzadeh, S. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.104836 · Cited by 116
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
Alrubayyi, A., Gea‐Mallorquí, E., Touizer, E., Hameiri‐Bowen, D., Kopycinski, J. T., Charlton, B. G., Fisher-Pearson, N., Muir, L., Rosa, A., Roustan, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26137-7 · Cited by 115
Chavarot, N., Morel, A., Leruez‐Ville, M., Vilain, E., Divard, G., Burger, C., Serris, A., Sberro‐Soussan, R., Martinez, F., Amrouche, L., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16814 · Cited by 109
B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients
Schrezenmeier, E. V., Rincón-Arévalo, H., Stefanski, A., Potekhin, A., Straub-Hohenbleicher, H., Choi, M., Bachmann, F., Proß, V., Hammett, C., Schrezenmeier, H., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070966 · Cited by 110
Self-citationSchrezenmeier, E. V., Rincón-Arévalo, H., Jens, A., Stefanski, A., Hammett, C., Osmanodja, B., Koch, N., Zukunft, B., Beck, J., Oellerich, M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157836 · Cited by 103
“All experiments were performed as previously described (4, 5, 18).”
Self-citationKim, E.-H., Nguyen, Q. T., Casel, M. A. B., Rollon, R., Kim, S., Kim, Y., Yu, K.-M., Jang, S., Yang, J., Poo, H., et al. (2022) · Journal of Virology · doi:10.1128/jvi.01873-21 · Cited by 102
Anand, U., Jakhmola, S., Indari, O., Jha, H. C., Chen, Z., Tripathi, V. S., & de la Lastra, J. M. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658519 · Cited by 94
“The CD4+ cells showed impaired function as well as alleviated IFN-g secretion in severe COVID-19 patients with higher age and comorbidity index (127).”
BackgroundTherapeutic potential of ginger against COVID-19: Is there enough evidence?
Jafarzadeh, A., Jafarzadeh, S., & Nemati, M. (2021) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2021.10.001 · Cited by 109
Immunity to SARS-CoV-2 up to 15 months after infection
Marcotte, H., Piralla, A., Zuo, F., Du, L., Cassaniti, I., Wan, H., Kumagai‐Braesch, M., Andréll, J., Percivalle, E., Sammartino, J. C., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103743 · Cited by 87
“Specific IFN-g producing Th1 CD4 + and cytotoxic CD8 + effector cells are considered important in supporting immunity against SARS-CoV-2 (Sattler et al., 2020).”
Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2
Woldemeskel, B. A., Kwaa, A. K., Garliss, C. C., Laeyendecker, O., Ray, S. C., & Blankson, J. N. (2020) · Journal of Clinical Investigation · doi:10.1172/jci143120 · Cited by 78
Multiscale PHATE identifies multimodal signatures of COVID-19
Kuchroo, M., Huang, J., Wong, P., Grenier, J.-C., Shung, D., Tong, A., Lucas, C., Klein, J., Burkhardt, D. B., Gigante, S., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01186-x · Cited by 72
Koerber, N., Priller, A., Yazici, S., Bauer, T., Cheng, C., Mijočević, H., Wintersteller, H., Jeske, S. D., Vogel, E., Feuerherd, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27649-y · Cited by 78
Bertoletti, A., Tan, A. T., & Bert, N. L. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab006 · Cited by 74
“These data are in accordance also with results obtained in patients with severe COVID-19 who display lower quantities and lower functionality of SARS-CoV-2-specific T cells than patients with mild disease [19,38].”
BackgroundResultZhang, H., Deng, S., Ren, L., Zheng, P., Hu, X., Jin, T., & Tan, X. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109708 · Cited by 71
“In a number of studies, cellular immunity has been shown to strongly correlate with disease outcome (Le Bert et al., 2021; Sattler et al., 2020; Sekine et al., 2020; Tan et al., 2021; Weiskopf et al., 2020), which indicates the importance of understanding the difference in cellular immunity for the various variants.”
Duration of post–COVID-19 symptoms is associated with sustained SARS-CoV-2–specific immune responses
Files, J. K., Sarkar, S., Fram, T., Boppana, S., Sterrett, S., Qin, K., Bansal, A., Long, D. M., Sabbaj, S., Kobie, J. J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151544 · Cited by 83
“5 (30-208) 10 (1-20) Hospitalized during COVID-19 infection 10 (20%) 10 (50%) 0 (0%) Peak Ordinal Score 2 (2-7) 3 (2-7) 2 (2-2) Age 51 (20-86) 51.”
BackgroundCovid-19 a triggering factor of autoimmune and multi-inflammatory diseases
Sher, E. K., Ćosović, A., Džidić-Krivić, A., Farhat, E. K., Pinjić, E., & Sher, F. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121531 · Cited by 70
Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion
Mazzoni, A., Salvati, L., Maggi, L., Annunziato, F., & Cosmi, L. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101508 · Cited by 80
Mazzoni, A., Maggi, L., Capone, M., Spinicci, M., Salvati, L., Colao, M. G., Vanni, A., Kiros, S. T., Mencarini, J., Zammarchi, L., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202048915 · Cited by 64
Acute Kidney Injury in Severe COVID-19 Has Similarities to Sepsis-Associated Kidney Injury
Alexander, M. P., Mangalaparthi, K. K., Madugundu, A. K., Moyer, A. M., Adam, B., Mengel, M., Singh, S., Herrmann, S. M., Rule, A. D., Cheek, E. H., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.07.001 · Cited by 59
“The molecular signals of inflammation and immune activation observed in COVID-19 kidneys suggests a global antiviral response characterized by a macrophage and T-cellerich inflammation, and type II interferon production, as widely suggested by blood-based assays.(20,21) The CD4þ-dominant T-cell response, as we observe…”
BackgroundFavà, A., Donadeu, L., Sabé, N., Pernin, V., González‐Costello, J., Lladó, L., Meneghini, M., Charmetant, X., García‐Romero, E., Cachero, A., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16570 · Cited by 61
Gutiérrez‐Bautista, J. F., Rodríguez-Nicolás, A., Rosales‐Castillo, A., Jiménez, P., Garrido, F., Anderson, P. O., Ruiz‐Cabello, F., & López‐Ruz, M. Á. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.596553 · Cited by 63
Shen, L., Bard, J. D., Triche, T. J., Judkins, A. R., Biegel, J. A., & Gai, X. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1922097 · Cited by 68
“In COVID-19 due to SARS-CoV-2, T-cell response has been identi fi ed as a critical determinant of outcome, with poor T-cell response to M protein epitopes found in patients with fatal outcome [17, 18].”
SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects
Zhao, J., Wang, L., Schank, M., Dang, X., Lu, Z., Cao, D., Khanal, S., Nguyen, L. N., Nguyen, L. N., Zhang, J., et al. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198508 · Cited by 51
Valdez‐Cruz, N. A., García‐Hernández, E., Espitia, C., Cobos-Marín, L., Altamirano, C., Bando-Campos, C. G., Cofas‐Vargas, L. F., Coronado-Aceves, E. W., González-Hernández, R. A., Hernández‐Peralta, P., et al. (2021) · Microbial Cell Factories · doi:10.1186/s12934-021-01576-5 · Cited by 57
“Moreover, these cells show an increase in IL-2 secretion and a diminishing in the IFN-γ production [98].”
BackgroundLozano‐Rodríguez, R., Valentín‐Quiroga, J., Ortiz, J. A., Martín‐Quirós, A., Pascual‐Iglesias, A., Terrón‐Arcos, V., Montalbán-Hernández, K. M., Casalvilla‐Dueñas, J. C., Bergón-Gutiérrez, M., Alcamí, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110235 · Cited by 54
“Of note, high levels of SARS-CoV-2 spike-specific CD4 T cells correlate with a lower COVID-19 predisposition (Sattler et al., 2020), stressing the relevance of a robust cellular response.”
Smit, M. J., Sander, A. F., Ariaans, M. B. P. A., Fougeroux, C. E., Heinzel, C., Fendel, R., Esen, M., Kremsner, P. G., ter Heine, R., Wertheim, H. F. L., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00337-8 · Cited by 50
Dysregulated Immune Responses in SARS-CoV-2-Infected Patients: A Comprehensive Overview
Kudryavtsev, I. V., Rubinstein, A., Головкин, А. С., Kalinina, O., Vasilyev, K., Георгиевна, Р. Л., & Isakova–Sivak, I. (2022) · Viruses · doi:10.3390/v14051082 · Cited by 50
“On the other hand, in aged individuals who are prone to a severe course of COVID-19, the levels of IFNγ-producing virus-specific cells decreased, which implied the importance of Th1 cells in the development of protective immune response [100].”
BackgroundIdentifying SARS‐CoV‐2 ‘memory’ NK cells from COVID‐19 convalescent donors for adoptive cell therapy
Herrera, L., Martin‐Inaraja, M., Santos, S. J., Inglés‐Ferrándiz, M., Azkarate, A., Pérez-Vaquero, M. Á., Vesga, M. Á., Vicario, J. L., Soria, B., Solano, C., et al. (2021) · Immunology · doi:10.1111/imm.13432 · Cited by 46
“NK cells were stimulated with individual and pooled SARS- CoV- 2 peptides (M, N, S) (Miltenyi) [41] at a final concentration of 0·6 nmol/ml.”
MethodChaurasia, P., Nguyen, T. H. O., Rowntree, L. C., Juno, J. A., Wheatley, A. K., Kent, S. J., Kedzierska, K., Rossjohn, J., & Petersen, J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101065 · Cited by 47
Santer, D. M., Li, D., Ghosheh, Y., Zahoor, M. A., Prajapati, D., Hansen, B. E., Tyrrell, D. L., Feld, J. J., & Gehring, A. J. (2022) · Nature Communications · doi:10.1038/s41467-022-34709-4 · Cited by 50
Malipiero, G., Moratto, A., Infantino, M. G., D’Agaro, P., Piscianz, E., Manfredi, M., Grossi, V., Benvenuti, E., Bulgaresi, M., Benucci, M., et al. (2021) · Immunologic Research · doi:10.1007/s12026-021-09226-z · Cited by 48
“The study was approved by the local ethical committee and assigned the internal protocol number 034 2020H EPIDEMIOLOGIA COVID-19.”
BackgroundInfluentialKumar, V. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106980 · Cited by 44
“All acute COVID-19 patients show specific CD4+T cells against, S, M, and N proteins of SARS-CoV2 [230].”
BackgroundInfluentialPrakash, S., Dhanushkodi, N. R., Zayou, L., Ibraim, I. C., Quadiri, A., Coulon, P.-G. A., Tifrea, D. F., Suzer, B., Shaik, A. M., Chilukuri, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328905 · Cited by 46
Metabolic imbalance of T cells in COVID-19 is hallmarked by basigin and mitigated by dexamethasone
Siska, P. J., Decking, S.-M., Babl, N., Matos, C., Bruss, C., Singer, K., Klitzke, J., Schön, M., Simeth, J., Köstler, J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148225 · Cited by 37
Du, X., Lipeng, S., Cao, W., Zuo, B., & Zhou, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0256429 · Cited by 37
“Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as a global pandemic since its outbreak in Wuhan, China, in December 2019 [1].”
BackgroundLow baseline IFN-γ response could predict hospitalization in COVID-19 patients
Crémoni, M., Allouche, J., Graça, D., Zorzi, K., Fernandez, C., Teisseyre, M., Benzaken, S., Ruetsch-Chelli, C., Esnault, V. L. M., Dellamonica, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953502 · Cited by 46
Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients
Caldrer, S., Mazzi, C., Bernardi, M., Prato, M. G., Ronzoni, N., Rodari, P., Angheben, A., Piubelli, C., & Tiberti, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.789735 · Cited by 45
CXCR3-Expressing T Cells in Infections and Autoimmunity
Rubinstein, A., Kudryavtsev, I. V., Arsentieva, N. A., Korobova, Z. R., Isakov, D., & Тотолян, А. А. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2908301 · Cited by 48
“On the other hand, older patients with typically severe COVID-19 had decreased level of IFN γ -producing virus-specific Th1 cells, which also indirectly indicates crucial role of these cells in developing effective immune response [130].”
Molodtsov, I. A., Kegeles, E., Mitin, A. N., Mityaeva, O. N., Musatova, O. E., Panova, A. E., Pashenkov, M. V., Peshkova, I. O., Alsalloum, A., Asaad, W., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac278 · Cited by 35
Viana, J. F., Bergman, M., Gonçalves, L. A., Duarte, N., Coutinho, T. P., Borges, P., Diwo, C., Castro, R., Matoso, P., Malheiro, V., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27761-z · Cited by 39
Spoerl, S., Kremer, A. N., Aigner, M., Eisenhauer, N., Koch, P., Meretuk, L., Löffler, P., Tenbusch, M., Maier, C., Überla, K., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202049135 · Cited by 36
Meyer‐Arndt, L., Braun, J., Fauchère, F., Vanshylla, K., Loyal, L., Henze, L., Kruse, B., Dingeldey, M., Jürchott, K., Mangold, M., et al. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329395 · Cited by 35
Bidar, F., Hamada, S., Gossez, M., Coudereau, R., Lopez, J., Cazalis, M.-A., Tardiveau, C., Brengel‐Pesce, K., Mommert, M., Buisson, M., et al. (2022) · Annals of Intensive Care · doi:10.1186/s13613-022-00982-1 · Cited by 33
“the co-inhibitory receptors PD-1, CTLA-4 or TIM-3 have been reported [35, 37, 38] and associated with disease severity in COVID-19 patients.”
BackgroundAge-related differences in immune dynamics during SARS-CoV-2 infection in rhesus macaques
Speranza, E. E., Purushotham, J. N., Port, J. R., Schwarz, B. H., Flagg, M., Williamson, B. N., Feldmann, F., Singh, M., Pérez-Pérez, L., Sturdevant, G. L., et al. (2022) · Life Science Alliance · doi:10.26508/lsa.202101314 · Cited by 32
“The efficient stimulation of virus-specific IFN-γ–secreting T cells is associated with decreased COVID-19 severity in humans (40).”
BackgroundSARS-CoV-2 and Multiple Sclerosis: Potential for Disease Exacerbation
MacDougall, M., Sleiman, J. E.-H., Beauchemin, P., & Rangachari, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871276 · Cited by 33
Essa, R. Z., Wu, Y. S., Batumalaie, K., Sekar, M., & Poh, C. L. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00432-6 · Cited by 30
“Cellular responses that have been characterized during acute infection include increased SARS-CoV-2N and S protein-specific CD4 + T-cells [45].”
BackgroundCOVID-19 Heart Lesions in Children: Clinical, Diagnostic and Immunological Changes
Vasichkina, E. S., Alekseeva, D. Y., Kudryavtsev, I. V., Glushkova, A. V., Starshinova, A. Y., Malkova, A. M., Kudlay, D. A., & Starshinova, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021147 · Cited by 38
“It also indirectly indicates the important role of Th1 cells in the development of an effective immune response [79].”
BackgroundReactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology
Steiner, S., Schwarz, T., Corman, V. M., Sotzny, F., Bauer, S., Drosten, C., Volk, H., Scheibenbogen, C., & Hanitsch, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687449 · Cited by 32
“Different time points of T cell analysis and mild disease course might also explain the lower expression of IL-2 in our patients (28, 29).”
BackgroundMurray, M. J., McIntosh, M., Atkinson, C. E., Mahungu, T. W., Wright, E., Chatterton, W., Gandy, M., & Reeves, M. B. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.03.010 · Cited by 33
Du, X., Shi, L., Cao, W., Chen, Z., Zuo, B., & Hu, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.708636 · Cited by 28
Gabitzsch, E., Safrit, J. T., Verma, M. S., Rice, A., Sieling, P. A., Zakin, L., Shin, A., Morimoto, B., Adisetiyo, H., Wong, R. M. H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.729837 · Cited by 25
“N also plays an important role in T-cell responses (47, 48).”
BackgroundThe Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines
Sun, Z., Wu, T., Xie, H., Li, Y., Zhang, J., Su, X., & Qi, H. (2022) · Vaccines · doi:10.3390/vaccines10071103 · Cited by 31
“A study found that patients who died of COVID-19 had fewer IFN-γ-secreting CD4+ T cells than those with mild illness and rehabilitation [74].”
BackgroundCharacterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIVPreprint
Alrubayyi, A., Gea‐Mallorquí, E., Touizer, E., Hameiri‐Bowen, D., Kopycinski, J. T., Charlton, B. G., Fisher-Pearson, N., Muir, L., Rosa, A., Roustan, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.15.431215 · Cited by 28
COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
Rnjak, D., Ravlić, S., Šola, A. M., Halassy, B., Šemnički, J., Šuperba, M., Hečimović, A., Kurolt, I.-C., Kurtović, T., Šafranko, Ž. M., et al. (2021) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2021.04.004 · Cited by 25
Impaired Priming of SARS-CoV-2-Specific Naive CD8+ T Cells in Older Subjects
Gallerani, E., Proietto, D., Dallan, B., Campagnaro, M., Pacifico, S., Albanese, V., Marzola, E., Marconi, P., Caputo, A., Appay, V., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693054 · Cited by 31
“Although few studies investigated agespecific patterns of antiviral immunity, it has been shown that elderly infected patients harbor low frequencies of virus-specific CD8 T cells (4), and age correlates with few IFNg-producing T cells (2, 8).”
BackgroundSchultze-Florey, C. R., Chukhno, E., Goudeva, L., Blasczyk, R., Ganser, A., Prinz, I., Förster, R., Koenecke, C., & Odak, I. (2021) · Leukemia · doi:10.1038/s41375-021-01348-5 · Cited by 26
Heterogeneous magnitude of immunological memory to SARS‐CoV‐2 in recovered individuals
Mazzoni, A., Maggi, L., Capone, M., Vanni, A., Spinicci, M., Salvati, L., Kiros, S. T., Semeraro, R., Pengue, L., Colao, M. G., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1281 · Cited by 25
“Moreover, a dysregulated immune response has been observed in critically ill COVID-19 patients.(8,9) While some data are now available regarding the characterisation of virus-specific immune response in the acute or early convalescent phase of the disease, there are instead a few studies investigating long-term immuni…”
BackgroundSARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity
Kim, J. Y., Kwon, J., Bae, S., Cha, H. H., Lim, J. S., Kim, M., Chung, J.-W., Park, S. Y., Lee, M. J., Kim, B.-N., et al. (2021) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.20-1594 · Cited by 26
A single transcript for the prognosis of disease severity in COVID-19 patients
Lei, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-91754-7 · Cited by 27
Immunity after SARS-CoV-2 infections
Jagannathan, P., & Wang, T. T. (2021) · Nature Immunology · doi:10.1038/s41590-021-00923-3 · Cited by 27
Guo, Y., Li, T., Xia, X., Su, B., Li, H., Feng, Y., Han, J., Wang, X., Jia, L., Bao, Z., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.723585 · Cited by 22
Immune interventions in COVID-19: a matter of time?
Plaçais, L., Richier, Q., Noël, N., Lacombe, K., Mariette, X., & Hermine, O. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00464-w · Cited by 22
Hybrid Immunity against SARS-CoV-2 Variants: A Narrative Review of the Literature
Tsagkli, P., Geropeppa, M., Papadatou, I., & Spoulou, V. I. (2024) · Vaccines · doi:10.3390/vaccines12091051 · Cited by 30
“…in SARS-CoV-2-specific CD4 + T-cell responses has been observed, concomitantly to the reported heterogeneity in clinical outcomes of the infection [12], as CD4 + T-cell frequencies are influenced by older age and comorbidities [28], while gender has no effect on CD4 + T-cell responses [12,13].”
BackgroundShankar‐Hari, M., François, B., Remy, K. E., Gutiérrez, C., Pastores, S. M., Daix, T., Jeannet, R., Blood, J., Walton, A. H., Salomão, R., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.189150 · Cited by 27
Ghazizadeh, H., Shakour, N., Ghoflchi, S., Mansoori, A., Saberi‐Karimian, M., Rashidmayvan, M., Ferns, G. A., Esmaily, H., & Ghayour‐Mobarhan, M. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02495-4 · Cited by 23
“found that there is a relationship between susceptibility to disease in each individual and underlying diseases and disruption of Th1 type cell immunity [53].”
BackgroundPattern Recognition Proteins: First Line of Defense Against Coronaviruses
Labarrere, C. A., & Kassab, G. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652252 · Cited by 24
Coulon, P.-G. A., Prakash, S., Dhanushkodi, N. R., Srivastava, R., Zayou, L., Tifrea, D. F., Edwards, R. A., Figueroa, C. J., Schubl, S. D., Hsieh, L. L., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1343716 · Cited by 21
Phenotypes and Functions of SARS-CoV-2-Reactive T Cells
Jung, M. K., & Shin, E. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0079 · Cited by 20
“However, contradictory results have been reported (Peng et al., 2020; Sattler et al., 2020; Sekine et al., 2020; Tan et al., 2021).”
Sidhom, J.-W., & Baras, A. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-93608-8 · Cited by 22
“Days from onset to sample (IQR)—days 18 (13-25) 13 (9-21)”
Xiao, C., Mao, L., Wang, Z., Gao, L., Zhu, G., Su, J., Chen, X., Yuan, J., Hu, Y., Yin, Z., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103934 · Cited by 23
“, 2020) (Sattler et al., 2020) and SARS-CoV-2 vaccinees(Jackson et al.”
BackgroundKrishnan, A., Gangadaran, P., Chavda, V. P., Jogalekar, M. P., Ramesh, M., Valu, D., Vadivalagan, C., Ramani, P., Laishevtcev, A. I., Katari, N. K., et al. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221092984 · Cited by 23
Thurm, C., Reinhold, A., Borucki, K., Kahlfuß, S., Feist, E., Schreiber, J., Reinhold, D., & Schraven, B. L. (2022) · Vaccines · doi:10.3390/vaccines10020333 · Cited by 19
Palladino, G., Chang, C. W., Lee, C., Music, N., de Souza, I. P., Nolasco, J., Amoah, S., Suphaphiphat, P., Otten, G. R., Settembre, E. C., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.013 · Cited by 21
Seddiki, N., & French, M. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.649567 · Cited by 20
Welch, J. L., Xiang, J., Chang, Q., Houtman, J. C. D., & Stapleton, J. T. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab595 · Cited by 19
Melton, A., Doyle‐Meyers, L. A., Blair, R. V., Midkiff, C. C., Melton, H. J., Russell‐Lodrigue, K., Aye, P. P., Schiro, F. R., Fahlberg, M. D., Szeltner, D. M., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010162 · Cited by 21
Schmidt, K. G., Nganou‐Makamdop, K., Tenbusch, M., Kenz, B. E., Maier, C., Lapuente, D., Überla, K., Spriewald, B. M., Bergmann, S., Harrer, E. G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627568 · Cited by 18
Terrec, F., Jouvé, T., Malvezzi, P., Janbon, B., Bennani, H. N., Rostaing, L. P. E., & Noble, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215159 · Cited by 22
“have recently shown that most spike-specific Th cells express the co-activating molecule CD28; and could therefore become theoretically inhibited by belatacept [23].”
BackgroundTran, H. T. T., Peterburs, P., Seibel, J., Abramov-Sommariva, D., & Lamy, E. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/8038195 · Cited by 17
Endothelial cell, myeloid, and adaptive immune responses in SARS‐CoV‐2 infection
Degauque, N., Haziot, A., Brouard, S., & Mooney, N. (2021) · The FASEB Journal · doi:10.1096/fj.202100024r · Cited by 14
An update on host immunity correlates and prospects of re-infection in COVID-19
Negi, N., Maurya, S. P., Singh, R., & Das, B. K. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.2019727 · Cited by 23
Soto, J. A., Díaz, F. E., Retamal-Díaz, A. R., Gálvez, N. M. S., Melo-González, F., Piña-Iturbe, A., Ramírez, M. A., Böhmwald, K., González, P. A., Bueno, S. M., et al. (2022) · Vaccines · doi:10.3390/vaccines10050721 · Cited by 24
“Several Orthohantavirus species have been recognized as aetiological agents of HCPS, including the Sin Nombre orthohantavirus (SNV) and Andes orthohantavirus (ANDV) as the most relevant species in North America and South America, respectively [30,31].”
BackgroundEar, nose, and throat manifestations of COVID-19 and its vaccines
Al-Ani, R. M. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i25.8808 · Cited by 20
Gabitzsch, E., Safrit, J. T., Verma, M., Rice, A., Sieling, P. A., Zakin, L., Shin, A., Morimoto, B., Adisetiyo, H., Wong, R. M. H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.08.416297 · Cited by 17
“The relatively greater rebound of lymphocytes in vaccinated NHP could be due to proliferation of a subset of T lymphocytes in response to SARS-CoV-2-specific infection (16, 26, 27), a hypothesis that awaits confirmation.”
BackgroundFerreira, V. H., Marinelli, T. M., Ierullo, M., Ku, T., Hall, V. G., Majchrzak-Kita, B., Kulasingam, V., Humar, A., & Kumar, D. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab542 · Cited by 18
“The overall magnitude of antigen-specific CD4 and CD8 Tcell response measured in our study is similar to the proportion observed for the general population [7, 10-15], along with the directionality of T-cell responses against S and NP antigens.”
BackgroundResultInfluentialAugello, M., Bono, V., Rovito, R., Tincati, C., Bianchi, S., Taramasso, L., Biagio, A. D., Callegaro, A., Maggiolo, F., Borghi, E., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108673 · Cited by 16
Metadata
- Authors
- Sattler, A., Angermair, S., Stockmann, H., Heim, K. M., Khadzhynov, D., Treskatsch, S., Halleck, F., Kreis, M. E., & Kotsch, K.
- Corresponding author
- Sattler, Arne
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-11-03
- Volume
- 130
- Issue
- 12
- Pages
- 6477-6489
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7685725
- OpenAlex
- W3080524815
- Cited by
- 196
- References
- 55
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 14 · 2023: 25 · 2022: 52 · 2021: 80 · 2020: 10
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sonnenfeldstiftung (FACS facility support)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- SARS-CoV-2, COVID-19 pandemic, T cell response, CD4+ T helper cells, cell-mediated immunity, membrane proteins, nucleocapsid protein, spike protein, Th1 response, PD-1, interleukin-2, interferon-gamma, age, comorbidities, APACHE II score, mortality, intensive care, disease severity
- MeSH terms
- COVID-19, SARS-CoV-2, Adult, Age Factors, Aged, Aged, 80 and over, Disease Susceptibility, Female, Humans, Interferon-gamma, Interleukin-2, Male, Middle Aged, Severity of Illness Index, Th1 Cells, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.